Microneedle-mediated intradermal delivery of methotrexate alleviates imiquimod-induced initial and recurrent psoriasis-like skin inflammation by inhibiting IL-17A+Vγ4+ γδT cells

Microneedle-mediated intradermal delivery of methotrexate alleviates imiquimod-induced initial and recurrent psoriasis-like skin inflammation by inhibiting IL-17A⁺Vγ4⁺ γδT cells

J Invest Dermatol. 2025 Jun 24:S0022-202X(25)02147-5. doi: 10.1016/j.jid.2025.05.039. Online ahead of print.

¹ Hubei Engineering Research Center for Skin Repair and Theranostics, Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan 430022, China.
² Hubei Engineering Research Center for Biomaterials and Medical Protective Materials, School of Chemistry and Chemical Engineering, HUST, Wuhan 430074, China.
³ Hubei Engineering Research Center for Skin Repair and Theranostics, Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan 430022, China. Electronic address: tjhappy@126.com.

No abstract available

Keywords: IMQ-induced psoriasis-like skin inflammation; methotrexate; microneedle; psoriasis; recurrence.